This article is more than 5 years old. Information may no longer be current.

B&L, InSite Vision to develop fluoroquinolone delivery system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch & Lomb and InSite Vision have agreed to develop and market a product for treatment of ocular bacterial infections. ISV-403 combines a fourth-generation fluoroquinolone, licensed from Japanese firm SSP Co. Ltd., with InSite's patented drug delivery system. Preclinical studies on the fluoroquinolone indicate it “is effective against bacteria that are resistant to the currently marketed fluoroquinolone products,” according to a news release issued by both companies.

InSite will develop the drug and Bausch & Lomb will be responsible for commercial manufacturing and marketing. Bausch & Lomb was granted worldwide marketing exclusivity, excluding Japan, and will share marketing rights in Asia.